GlassScriptPhysician profile
Araya Zaesim
NPI 1588142517
$8,088.63
in general payments reported to CMS, 2019-2025
28 companies · $2,453 in 2025
The $2,453 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $362 · 2022: $862 · 2023: $1,437 · 2024: $2,975 · 2025: $2,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,468 · Education: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,468.43 |
| Education | $396.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,552.53 | 2021-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $721.56 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $606.55 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $435.57 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $432.22 | 2023-2025 | |
| Ucb, INC. | $406.75 | 2024-2025 | Bimzelx |
| Incyte Corporation | $391.69 | 2023-2025 | Opzelura, Opzelura |
| Amgen INC. | $367.26 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $321.46 | 2022-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $238.17 | 2023-2025 | Adbry |
| Galderma Laboratories, L.P. | $212.13 | 2024-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $202.75 | 2023-2025 | Zoryve |
| Genzyme Corporation | $202.68 | 2022-2025 | |
| Organogenesis INC. | $163.42 | 2023-2024 | Puraply |
| Dermavant Sciences, INC. | $154.64 | 2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $128.20 | 2023-2025 | Ilumya |
| Pfizer INC. | $111.73 | 2023 | |
| Kyowa Kirin, INC. | $90.24 | 2023 | Poteligeo |
| Almirall LLC | $84.70 | 2024 | Seysara, Klisyri |
| Kerecis Limited | $78.14 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.60 | 2023-2024 | Spevigo, Cyltezo |
| Convatec INC. | $39.08 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.54 | 2024 | Cabtreo |
| Hydrofera LLC | $20.89 | 2025 | Hydrofera Blue |
| Mallinckrodt Hospital Products INC. | $17.71 | 2025 | Acthar |
| Genentech USA, INC. | $14.89 | 2024 | Erivedge |
| Organon LLC | $14.37 | 2024-2025 | Vtama |
| Biofrontera INC. | $11.16 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Araya Zaesim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.